Despite different isoform-selective PI3K inhibitors, such as BYL719, MLN1117, CAL-101, GSK2636771, and CH5132799, entered phase I/II clinical trials to study their potential on solid tumors and hematologic malignancies, no clinical studies have yet been addressed on GBM patients [125]. This evidence concerns the gene PIK3CA and glioblastoma.